Martin Gargaros
Director at MBX Capital
New York, New York
Overview
Work Experience
Director
2024 - Current
MBX is a venture capital partnership focused on emerging companies pursuing critical challenges in public health. We invest between $500K and $5mm into early-stage bio/health-tech companies. Learn more at mbxcapital.com
MBX Capital is a venture capital partnership investing in early-stage healthcare, life sciences, and environmental health companies
Director, Strategic Finance
2016 - 2024
V3 Commodities Group provides physical energy commodity products and services alongside capital support to retail energy providers operating in the North American energy markets. We also provide M&A services related to the acquisition and disposition of assets related to the sector.
V3 Commodities is a NY-based capital and risk management services company.
Raised $50,000,000.00 from Colbeck Capital.
Corporate Development
2018 - 2019
Mergers and acquisitions for Roivant Sciences, Inc., as of early 2020 a $9B market cap healthcare firm with ~20 portfolio biopharma companies developing treatments for 35+ indications across a range of therapeutic areas and modalities
Roivant Sciences is a biopharmaceutical company focused on the development of medicines and healthcare technologies to patients.
Raised $2,473,000,000.00 from Eventide, Fidelity, Viking Global Investors, RTW Investments, Patient Square Capital, Palantir Technologies, Dainippon Sumitomo Pharma, Suvretta Capital Management and SoftBank Capital.